AEON Biopharma, Inc.

$0.71
(as of Jun 24, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for AEON Biopharma, Inc.

Stock Price
$0.71
Ticker Symbol
AEON
Exchange
NYSE MKT

Industry Information for AEON Biopharma, Inc.

Sector
Healthcare
Industry
Biotechnology

Company Description for AEON Biopharma, Inc.

Country
USA
Full Time Employees
5

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Fundamentals for AEON Biopharma, Inc.

Market Capitalization
$8,411,218
EBITDA
$-21,302,000
Dividends per Share
P/E Ratio
0
Forward P/E Ratio
1.16
Earnings per Share
$303.08
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
11,305,400
Percent Owned by Insiders
24.46%
Percent Owned by Institutions
14.66%
52-Week High
52-Week Low

Technical Indicators for AEON Biopharma, Inc.

50-Day Moving Average
200-Day Moving Average
RSI
47.81
0.09

Analyst Ratings for AEON Biopharma, Inc.

Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0

News About AEON Biopharma, Inc.

May 23, 2025, 4:05 PM EST
IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. See more.
May 19, 2025, 4:05 PM EST
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. See more.
May 14, 2025, 4:05 PM EST
– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – See more.
Apr 25, 2025, 4:05 PM EST
IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. See more.